See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter ↵ to review claims
Explore by Goal
"The scientist only imposes two things, namely truth and sincerity, imposes them upon himself and upon other scientists."
- Erwin Schrödinger
Quick Explanation
Copied
Richard B. Kennedy — scientific strength (skeptical, evidence-weighted): a high-output, immunology/vaccinology–heavy researcher with strong quantitative/systems approaches (genomics/transcriptomics/immunogenetics), but—based on the limited raw extracts you provided—many findings remain at the “mechanism/predictor” level (often human observational or in vitro), so generalizability and causal inference need careful validation.
Long Explanation
Author Review: Richard B. Kennedy
Critical, evidence-based synthesis focused on scientific rigor, evidence strength, and falsifiability.
1) Productivity & impact snapshot (from your provided metrics)
h-index: 46 (from your provided dataset); note this may differ from other databases.
Total citations: 6851 (from your provided dataset).
Publication count: 156 (from your provided dataset).
OpenAlex (separate database view): top match shows works_count=283 and h_index=51 for “Richard B. Kennedy” (from your provided OpenAlex snippet), but database deduplication/author disambiguation can change these values.
2) Temporal profile of cited-by counts (OpenAlex snippet)
3) Evidence deep-dive from two raw paper extracts you provided
3A. Mechanism study example (BRCA1 ↔ MEKK3; paclitaxel response)
Key mechanistic claims supported by the extracted methods/results
Physical/biochemical interaction: BRCA1 binds MEKK3 via BRCT motifs (yeast two-hybrid and co-IP supported), and BRCT-domain mutations/constructs abolish or disrupt interaction.
Signal transduction: BRCA1 induction increases MEKK3 kinase activity and downstream p38 MAPK phosphorylation; BRCA1 knockdown reduces MEKK3 activity.
Chemotherapy coupling: paclitaxel activates MEKK3 in BRCA1-competent cells, while BRCA1 deficiency or disruptive BRCA1 constructs blunt this activation; BRCA1 reconstitution increases paclitaxel sensitivity and cleaved caspase-3.
Critical falsifiability note: the extract explicitly lists falsification criteria (paclitaxel-driven MEKK3 activation should not be BRCA1-dependent if the claim is wrong).
Biological caveats / blind spots (from the extracted limitations)
Predominantly cell-line–based and yeast-based evidence; in vivo relevance not demonstrated in the extracted summary.
Potential off-target effects from siRNA and the limitations of overexpression/reconstitution systems.
Generalizability across tumor types and patient tumors remains uncertain without patient-sample linkage.
Graph: Yeast two-hybrid positives vs downstream confirmation (from extracted counts)
Citation for this paper’s extracted mechanism/limitations:
3B. Neuroimmunology example (sex differences in early untreated PD monocyte activation)
Evidence-type: human bulk RNA-seq of sorted CD14+ monocytes; observational/cross-sectional; sex-stratified differential expression + pathway/module enrichment.
Key extracted findings
Design: early PD (≤2 years from symptom onset) and untreated participants; PBMC isolation → negative selection for CD14+ monocytes; RNA-seq on 34 samples total.
Sex as a driver: sex is reported as a major driver of monocyte gene expression; females show PD-associated inflammatory activation enriched for interferon-γ–linked programs.
Differential expression by sex: extracted counts report ~347 female DEGs vs ~15 male DEGs at q<0.10 (per extraction).
Validation: qRT-PCR validation supports several RNA-seq directionality signals (exact significance calls are gene-specific in the extracted summary).
Limitations (explicit): cross-sectional, modest sample size, bulk monocyte analysis (not single-cell), and lack of independent replication.
Graph: Differential expression counts by sex (extracted)
Graph: Cohort sample counts by sex (extracted)
Citation for this paper’s extracted design/findings/limitations:
4) Scientific strength assessment (what the extracts imply about the author’s style)
What appears strong
Mechanistic anchoring when possible: the BRCA1–MEKK3 example connects binding/mapping to biochemical signaling and then to a drug-response phenotype, which supports internal coherence of the causal chain.
High-dimensional immune profiling: the PD monocyte extract uses RNA-seq, pathway/module enrichment, and sex-stratified modeling rather than relying on single markers.
Explicit discussion of failure modes: both extracts include limitations/ways the claims could fail (e.g., in vitro generalization and cross-sectional confounding), which is consistent with scientific self-critique.
Key blind spots / risk points (skeptical view)
Generalization vs internal validity: mechanistic chains in vitro can be real but may not scale to living systems; the BRCA1 study explicitly lacks in vivo confirmation in the extracted summary.
Observational inference limits: sex-stratified DEG patterns in bulk RNA-seq are vulnerable to confounding (medication status, comorbidities, cell-composition shifts) and cannot alone establish causality for PD biology.
Reproducibility dependency on analysis choices: high-dimensional omics conclusions can shift with preprocessing, feature filtering, batch correction, and multiple-testing thresholds; the PD extract reports q-value thresholds and module mapping, but external replication is still essential.
5) How BGPT would evaluate “best evidence” for this author (process)
Prioritize studies where the author’s claim has both (i) direct experimental perturbation and (ii) an outcome phenotype within the same biological system (stronger causal chain).
For omics papers, require external replication or independent cohort validation before treating signature/module “predictors” as stable biology.
Check cell-model appropriateness: the stronger the mechanistic claim, the more the study should bridge to in vivo and/or patient sample correlations.
Feedback:
Updated: April 09, 2026
BGPT Author Review
Scientific Quality
70%
From the provided raw extracts, the author demonstrates strong ability to connect mechanistic perturbations to measurable signaling/phenotypes (BRCA1–MEKK3→paclitaxel response) and to use high-dimensional immunology/neuroimmunology profiling with sex-stratified analyses (bulk monocyte RNA-seq in early PD). However, both examples (as extracted) emphasize limitations common in biomedical research: in vitro/cell-line reliance for mechanistic claims and cross-sectional/bulk-omics constraints for observational sex-difference biology. Evidence strength appears moderate-to-good for internal validity; external validity and causal inference appear to require further independent replication and in vivo/patient-level confirmation.
Communication Quality
70%
Based on your extracts, the work communicates experimental logic and explicitly lists limitations and falsification routes. The main issue is that many key details (effect sizes, statistical models, replication) are not present in the provided snippets, so communication quality can’t be fully judged from what’s shown here.
Author Novelty
60%
The BRCA1–MEKK3 framing is a plausible integrative mechanism; the PD example highlights sex-specific immune signatures. Novelty looks more incremental-by-integration than completely paradigm-shifting based on the extracted descriptions alone.
Scientific Rigor
70%
The extracts show recognizable rigor patterns: mapping domains (yeast two-hybrid + constructs), biochemical assays (kinase activity, phosphorylation), reciprocal evidence (co-IP), and for RNA-seq, quality control, DEG thresholds, pathway/module enrichment, and qRT-PCR validation. Main rigor risks are reproducibility dependency in omics and limited external validation/in vivo bridging in the mechanism example.
Parses the two extracted counts tables, computes enrichment-like ratios (e.g., female vs male DEGs) and generates Plotly-ready summary arrays for visualization and discrepancy checks.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A single universal monocyte inflammatory signature explains early PD in both sexes equally; the extracted DEG asymmetry and module enrichment differences between females and males argue against this as a single best explanation.
BRCA1–MEKK3 interaction is merely a cell-line artifact with no functional consequences for paclitaxel response; the extracted dependence of paclitaxel-driven MEKK3 activation and apoptosis readouts on BRCA1 competence argues that this is unlikely as a complete explanation.
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion